Avastin advertising contracted before FDA decision

12/13/2011 | Medical Marketing & Media

Roche's Genentech unit reduced spending on journal ads for Avastin well before the FDA revoked approval for the drug to treat breast cancer. Genentech stopped promoting Avastin for breast cancer in August 2010 and reduced spending on journal ads for other indications in 2011, a spokeswoman said.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ